Does Humana Cover Wegovy?

Humana overview

Humana is one of the largest health insurance providers in the United States and a major presence in Virginia. The company operates both commercial health plans and one of the nation’s largest Medicare Advantage portfolios, making it a common carrier among patients we see at PEAK.

Understanding Humana’s coverage for Wegovy (semaglutide) requires separating two very different plan structures. Humana’s commercial plans and its Medicare Advantage plans follow different formulary rules, different regulatory frameworks, and different coverage criteria for anti-obesity medications. What applies to one does not apply to the other.

Commercial plan coverage

Humana commercial plans — including employer-sponsored group plans, individual marketplace plans, and self-funded employer plans administered by Humana — may cover Wegovy for chronic weight management. However, coverage is not guaranteed and varies significantly by plan design.

Factors that determine commercial plan coverage:

• Employer formulary decisions — For employer-sponsored plans, the employer (not Humana) often decides whether anti-obesity medications are included. Some employers have added Wegovy to their formulary; many have explicitly excluded weight loss drugs to control costs.
• Plan tier and formulary placement — When Wegovy is covered, it is typically placed on a specialty or non-preferred tier, which means higher copays or coinsurance compared to preferred medications.
• Weight loss medication exclusions — Some Humana commercial plans include blanket exclusions for anti-obesity medications. If your plan documents contain this exclusion, Wegovy will be denied regardless of clinical need.
• Prior authorization requirements — Even when Wegovy appears on the formulary, prior authorization is almost always required before coverage begins.

Medicare Advantage plans

Humana Medicare Advantage coverage for Wegovy requires a fundamentally different understanding than commercial coverage. Traditional Medicare Part D explicitly excludes medications prescribed for weight loss or cosmetic purposes. This exclusion has historically been the primary barrier for Medicare beneficiaries seeking GLP-1 medications.

Because Humana Medicare Advantage plans include Part D prescription drug coverage, they inherit this federal exclusion. If Wegovy is prescribed solely for chronic weight management, it will not be covered under a Humana Medicare Advantage plan — regardless of how medically necessary it may be.

This is where the cardiovascular indication changes everything for Humana Medicare Advantage members.

The cardiovascular exception for Humana MA

In March 2024, the FDA approved Wegovy for a second indication: reducing the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease who are overweight or obese. This approval was based on the landmark SELECT trial.

This second indication matters enormously for Humana Medicare Advantage members because it creates a pathway that falls outside the Part D weight loss exclusion. When Wegovy is prescribed for cardiovascular risk reduction — not weight loss — it may be eligible for Medicare Part D coverage.

To qualify through this pathway with Humana Medicare Advantage, you generally need:

• Established cardiovascular disease — Documented history of heart attack, stroke, peripheral artery disease, or other confirmed cardiovascular condition
• BMI of 27 or greater — Consistent with the FDA-approved population for the cardiovascular indication
• Prescriber documentation — Your clinician must specifically document that Wegovy is being prescribed for cardiovascular risk reduction, not weight management
• Supporting clinical evidence — Relevant cardiac history, imaging results, or specialist notes that confirm the cardiovascular diagnosis

Prior authorization for Humana

Humana requires prior authorization for Wegovy across virtually all plan types. The specific documentation requirements differ depending on whether you are on a commercial plan or a Medicare Advantage plan, and which indication is being used.

Commercial plan PA requirements

For Humana commercial plans covering Wegovy for weight management, the typical PA submission includes:

• Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Evidence of participation in a structured weight management program — typically diet, exercise, and behavioral counseling for 3 to 6 months
• Documentation that other weight management approaches have been attempted
• In some plans, step therapy completion with another anti-obesity medication before Wegovy is approved

Medicare Advantage PA requirements (cardiovascular pathway)

For Humana Medicare Advantage plans using the cardiovascular indication, documentation requirements include:

• Confirmed diagnosis of atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral arterial disease)
• BMI of 27 or greater
• Clinical rationale documenting that Wegovy is being prescribed for cardiovascular risk reduction
• Relevant cardiology records, imaging, or specialist documentation supporting the cardiovascular diagnosis

Appeals process

If Humana denies your prior authorization for Wegovy, you have the right to appeal. Humana’s appeals process follows specific timelines and procedures that vary by plan type.

Humana commercial plan appeals

• Standard appeal — You or your clinician can file a formal appeal within 180 days of the denial. Humana must issue a decision within 30 calendar days.
• Expedited appeal — If delaying treatment poses a serious health risk, your clinician can request an expedited review. Humana must respond within 72 hours.
• Peer-to-peer review — Your prescribing clinician can request a direct conversation with Humana’s medical director. This is often the most effective step when the initial denial was based on incomplete documentation.
• External review — If Humana upholds the denial on appeal, you may have the right to an independent external review by a third-party organization.

Humana Medicare Advantage appeals

• Redetermination — The first level of appeal for Medicare Advantage plans. Humana must issue a decision within 7 calendar days (72 hours for expedited).
• Reconsideration — If the redetermination is unfavorable, the case is reviewed by an Independent Review Entity (IRE), not by Humana. This adds an additional layer of impartial review.
• Administrative Law Judge hearing — For denials involving amounts above the annual threshold, you may request a hearing before an ALJ. This is a formal process with specific filing requirements.

Self-pay options at PEAK

PEAK does not accept Humana insurance. In our service area, Humana offers only Medicare plans, which PEAK does not accept. However, Humana members may be seen at PEAK on a self-pay basis.

If you have Humana and are interested in medical weight loss at PEAK, here is what to know:

• Self-pay pricing. Visit our pricing page for current self-pay rates for provider visits and dietitian appointments.
• Medication costs. Self-pay patients can use manufacturer savings programs, including NovoCare for Wegovy, to reduce medication costs independently of insurance.
• No insurance filing. Self-pay visits do not involve insurance claims, prior authorizations, or coverage restrictions.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.